Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse

Human Molecular Genetics

Volumn 19, Issue 17, 2010, Pages 3402-3412

  Glynn, Dervila ^a   Gibson, Helen E ^a   Harte, Michael K ^b   Reim, Kerstin ^c   Jones, Susan ^a   Reynolds, Gavin P ^b   Morton, A Jennifer ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; BRAIN PROTEIN; CLORGYLINE; COMPLEXIN 2; HOMOVANILLIC ACID; ISOPRENALINE; NEUROTRANSMITTER; NORADRENALIN; UNCLASSIFIED DRUG;

ARTICLE; COGNITION; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; HIPPOCAMPUS; IN VITRO STUDY; NEUROCHEMISTRY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SOCIAL INTERACTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; ANTIDEPRESSIVE AGENTS; CLORGYLINE; DISEASE MODELS, ANIMAL; FEMALE; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NERVE TISSUE PROTEINS; NERVOUS SYSTEM DISEASES; NOREPINEPHRINE;

ANIMALIA; MUS;

EID: 77955448684     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq252     Document Type: Article

References (55)

1. McMahon, H.T., Missler, M., Li, C. and Sudhof, T.C. (1995) Complexins: cytosolic proteins that regulate SNAP receptor function. Cell, 83, 111-119.
2. Reim, K., Wegmeyer, H., Brandstatter, J.H., Xue, M., Rosenmund, C., Dresbach, T., Hofmann, K. and Brose, N. (2005) Structurally and functionally unique complexins at retinal ribbon synapses. J. Cell Biol., 169, 669-680.
3. 2+-dependent neurotransmitter release. Cell, 104, 71-81.
4. Xue, M., Stradomska, A., Chen, H., Brose, N., Zhang, W., Rosenmund, C. and Reim, K. (2008) Complexins are facilitators of neurotransmitter release at mammalian central excitatory and inhibitory synapses. Proc. Natl Acad. Sci. USA, 105, 7875-7880.
5. Huntwork, S. and Littleton, J.T. (2007) A complexin fusion clamp regulates spontaneous neurotransmitter release and synaptic growth. Nat. Neurosci., 10, 1235-1237.
6. Giraudo, C.G., Eng, W.S., Melia, T.J. and Rothman, J.E. (2006) A clamping mechanism involved in SNARE-dependent exocytosis. Science, 313, 676-680.
7. 2+-synaptotagmin I. Nat. Struct. Mol. Biol., 13, 748-750.
8. Tang, J., Maximov, A., Shin, O.H., Dai, H., Rizo, J. and Sudhof, T.C. (2006) A complexin/synaptotagmin 1 switch controls fast synaptic vesicle exocytosis. Cell, 126, 1175-1187.
9. Melia, T.J. Jr. (2007) Putting the clamps on membrane fusion: how complexin sets the stage for calcium-mediated exocytosis. FEBS Lett., 581, 2131-2139.
10. Xue, M., Lin, Y.Q., Pan, H., Reim, K., Deng, H., Bellen, H.J. and Rosenmund, C. (2009) Tilting the balance between facilitatory and inhibitory functions of mammalian and Drosophila Complexins orchestrates synaptic vesicle exocytosis. Neuron, 64, 367-380.
11. Eastwood, S.L. and Harrison, P.J. (2000) Hippocampal synaptic pathology in schizophrenia, bipolar disorder and major depression: a study of complexin mRNAs. Mol. Psychiatry, 5, 425-432.
12. Eastwood, S.L. and Harrison, P.J. (2001) Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res. Bull., 55, 569-578.
13. Knable, M.B., Barci, B.M., Webster, M.J., Meador-Woodruff, J. and Torrey, E.F.; Stanley Neuropathology Consortium (2004) Molecular abnormalities of the hippocampus in severe psychiatric illness: postmortem findings from the Stanley Neuropathology Consortium. Mol. Psychiatry, 9, 609-620.
14. Sawada, K., Young, C.E., Barr, A.M., Longworth, K., Takahashi, S., Arango, V., Mann, J.J., Dwork, A.J., Falkai, P., Phillips, A.G. and Honer, W.G. (2002) Altered immunoreactivity of complexin protein in prefrontal cortex in severe mental illness. Mol. Psychiatry, 7, 484-492.
15. Morton, A.J., Faull, R.L. and Edwardson, J.M. (2001) Abnormalities in the synaptic vesicle fusion machinery in Huntington's disease. Brain Res. Bull., 56, 111-117.
16. DiProspero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H. and Tagle, D.A. (2004) Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol., 33, 517-533.
17. Harrison, P.J. and Eastwood, S.L. (1998) Preferential involvement of excitatory neurons in medial temporal lobe in schizophrenia. Lancet, 352, 1669-1673.
18. Eastwood, S.L., Burnet, P.W. and Harrison, P.J. (2000) Expression of complexin I and II mRNAs and their regulation by antipsychotic drugs in the rat forebrain. Synapse, 36, 167-177.
19. Eastwood, S.L., Cotter, D. and Harrison, P.J. (2001) Cerebellar synaptic protein expression in schizophrenia. Neuroscience, 105, 219-229.
20. Eastwood, S.L. and Harrison, P.J. (2005) Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr. Res., 73, 159-172.
21. Sawada, K., Barr, A.M., Nakamura, M., Arima, K., Young, C.E., Dwork, A.J., Falkai, P., Phillips, A.G. and Honer, W.G. (2005) Hippocampal complexin proteins and cognitive dysfunction in schizophrenia. Arch. Gen. Psychiatry, 62, 263-272.
22. Basso, M., Giraudo, S., Corpillo, D., Bergamasco, B., Lopiano, L. and Fasano, M. (2004) Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics, 4, 3943-3952.
23. Tannenberg, R.K., Scott, H.L., Tannenberg, A.E. and Dodd, P.R. (2006) Selective loss of synaptic proteins in Alzheimer's disease: evidence for an increased severity with APOE varepsilon4. Neurochem. Int., 49, 631-639.
24. Zink, M., Vollmayr, B., Gebicke-Haerter, P.J., Henn, F.A. and Thome, J. (2007) Reduced expression of complexins I and II in rats bred for learned helplessness. Brain Res., 1144, 202-208.
25. Morton, A.J. and Edwardson, J.M. (2001) Progressive depletion of complexin II in a transgenic mouse model of Huntington's disease. J. Neurochem., 76, 166-172.
26. Edwardson, J.M., Wang, C.T., Gong, B., Wyttenbach, A., Bai, J., Jackson, M.B., Chapman, E.R. and Morton, A.J. (2003) Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J. Biol. Chem., 278, 30849-30853.
27. Freeman, W. and Morton, A.J. (2004) Differential messenger RNA expression of complexins in mouse brain. Brain Res. Bull., 63, 33-44.
28. Patel, S., Sinha, A. and Singh, M.P. (2007) Identification of differentially expressed proteins in striatum of maneb-and paraquat-induced Parkinson's disease phenotype in mouse. Neurotoxicol. Teratol., 29, 578-585.
29. Yamada, M., Saisu, H., Ishizuka, T., Takahashi, H. and Abe, T. (1999) Immunohistochemical distribution of the two isoforms of synaphin/complexin involved in neurotransmitter release: localization at the distinct central nervous system regions and synaptic types. Neuroscience, 93, 7-18.
30. Freeman, W. and Morton, A.J. (2004) Regional and progressive changes in brain expression of complexin II in a mouse transgenic for the Huntington's disease mutation. Brain Res. Bull., 63, 45-55.
31. Glynn, D., Drew, C.J., Reim, K., Brose, N. and Morton, A.J. (2005) Profound ataxia in complexin I knockout mice masks a complex phenotype that includes exploratory and habituation deficits. Hum. Mol. Genet., 14, 2369-2385.
32. Glynn, D., Sizemore, R.J. and Morton, A.J. (2007) Early motor development is abnormal in complexin 1 knockout mice. Neurobiol. Dis., 25, 483-495.
33. Drew, C.J., Kyd, R.J. and Morton, A.J. (2007) Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. Hum. Mol. Genet., 16, 2288-2305.
34. Glynn, D., Bortnick, R.A. and Morton, A.J. (2003) Complexin II is essential for normal neurological function in mice. Hum. Mol. Genet., 12, 2431-2448.
35. Gibson, H.E., Reim, K., Brose, N., Morton, A.J. and Jones, S. (2005) A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur. J. Neurosci., 22, 1701-1712.
36. Gray, R. and Johnston, D. (1987) Noradrenaline and beta-adrenoceptor agonists increase activity of voltage-dependent calcium channels in hippocampal neurons. Nature, 327, 620-622.
37. Cryan, J.F., Valentino, R.J. and Lucki, I. (2005) Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev., 29, 547-569.
38. Dyaglo, N.N. and Shishkina, G.T. (2000) Genetic differences in the synthesis and reception of noradrenaline in the mouse brain and behavior in a novel environment. Neurosci. Behav. Physiol., 30, 327-330.
39. Youdim, M.B.H., Edmondson, D. and Tipton, K.F. (2006) The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci., 7, 295-309.
40. Hopkins, W.F. and Johnston, D. (1984) Frequency-dependent noradrenergic modulation of long-term potentiation in the hippocampus. Science, 226, 350-352.
41. Hopkins, W.F. and Johnston, D. (1988) Noradrenergic enhancement of long-term potentiation at mossy fiber synapses in the hippocampus. J. Neurophysiol., 59, 667-687.
42. Huang, Y.Y. and Kandel, E.R. (1996) Modulation of both the early and the late phase of mossy fiber long-term potentiation by the activation of beta-adrenergic receptors. Neuron, 16, 611-617.
43. Bliss, T.V. and Collingridge, G.L. (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature, 361, 31-39.
44. Riedel, G., Micheau, J., Lam, A.G., Roloff, E.L., Martin, S.J., Bridge, H., de Hoz, L., Poeschel, B., McCulloch, J. and Morris, R.G. (1999) Reversible neural inactivation reveals hippocampal participation in several memory processes. Nat. Neurosci., 2, 898-905.
45. Coyle, J.T. and Duman, R.S. (2003) Finding the intracellular signaling pathways affected by mood disorder treatments. Neuron, 38, 157-160.
46. Garcia, R. (2002) Stress, metaplasticity, and antidepressants. Curr. Mol. Med., 2, 629-638.
47. Nestler, E.J., Gould, E., Manji, H., Buncan, M., Duman, R.S., Greshenfeld, H.K., Hen, R., Koester, S., Lederhendler, I., Meaney, M. et al. (2002) Preclinical models: status of basic research in depression. Biol. Psychiatry, 52, 503-528.
48. Schloss, P. and Henn, F.A. (2004) New insights into the mechanisms of antidepressant therapy. Pharmacol. Ther., 102, 47-60.
49. Brose, N. (2008) Altered complexin expression in psychiatric and neurological disorders: cause or consequence? Mol. Cells, 25, 7-19.
50. Zink, M., Rapp, S., Gebicke-Haerter, P.J., Henn, F.A. and Thome, J. (2005) Antidepressants differentially affect expression of complexin I and II RNA in rat hippocampus. Psychopharmacology (Berl)., 181, 560-565.
51. Ferguson, J.N., Young, L.J., Hearn, E.F., Matzuk, M.M., Insel, T.R. and Winslow, J.T. (2000) Social amnesia in mice lacking the oxytocin gene. Nat. Genet., 25, 284-288.
52. Porsolt, R.D., Le Pichon, M. and Jalfre, M. (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature, 266, 730-732.
53. Wood, N.I., Goodman, A.O., van der Burg, J.M., Gazeau, V., Brundin, P., Björkqvist, M., Petersén, A., Tabrizi, S.J., Barker, R.A. and Morton, A.J. (2008) Increased thirst and drinking in Huntington's disease and the R6/2 mouse. Brain Res. Bull., 76, 70-79.
54. van der Burg, J.M., Bacos, K., Wood, N.I., Lindqvist, A., Wierup, N., Woodman, B., Wamsteeker, J.I., Smith, R., Deierborg, T., Kuhar, M.J. et al. (2008) Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol. Dis., 29, 41-51.
55. Salin, P.A., Malenka, R.C. and Nicoll, R.A. (1996) Cyclic AMP mediates a presynaptic form of long-term potentiation at cerebellar parallel fiber synapses. Neuron, 16, 797-803.